Article Information
History
- July 17, 2022.
Article Versions
- You are currently viewing Version 1 of this article (July 17, 2022 - 08:48).
- Version 2 (September 23, 2022 - 08:07).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Hiroshi Yotsuyanagi, MD, PhD1,
- Norio Ohmagari, MD, PhD2,
- Yohei Doi, MD, PhD3,4,
- Takumi Imamura, MS5,
- Takuhiro Sonoyama, MD, PhD5,
- Genki Ichihashi, MPharm5,
- Takao Sanaki, PhD6,
- Yuko Tsuge, MS5,
- Takeki Uehara, PhD5,* and
- Hiroshi Mukae, MD, PhD7
- 1The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- 2Disease Control and Prevention Center, National Center for Global Health, Tokyo, Japan
- 3Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- 4Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan
- 5Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
- 6Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan
- 7Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
- ↵*Corresponding author
Takeki Uehara, Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Address: 8F, Nissay Yodoyabashi East, 3-3-13 Imabashi, Chuo-ku, Osaka 541-0042, Japan, Email: takeki.uehara{at}shionogi.co.jp, Telephone: +81-6-6209-6907
Posted July 17, 2022.
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: A protocol for a multicenter, randomized, double-blind, placebo-controlled, phase 3 study (the SCORPIO-SR trial)
